IO Biotech Net Income
| IOBT Stock | USD 0.28 0.01 3.45% |
As of the 3rd of February, IO Biotech owns the Information Ratio of (0.02), coefficient of variation of (8,188), and Market Risk Adjusted Performance of (0.49). IO Biotech technical analysis makes it possible for you to employ past data patterns with the intention to determine a pattern that calculates the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from IO Biotech's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting IO Biotech's valuation are summarized below:There are currently one hundred twenty fundamental measures for IO Biotech that can be evaluated and compared over time across peers in the sector. All traders should confirm IO Biotech's latest fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 135.3 M in 2026, whereas Enterprise Value is likely to drop slightly above 2.7 M in 2026. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -85.9 M | -90.2 M | |
| Net Loss | -64.3 M | -67.5 M | |
| Net Loss | -85.9 M | -90.2 M | |
| Net Loss | (1.30) | (1.37) | |
| Net Income Per E B T | 0.91 | 0.81 |
IOBT | Net Income | Build AI portfolio with IOBT Stock |
The evolution of Net Income for IO Biotech provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how IO Biotech compares to historical norms and industry peers.
Latest IO Biotech's Net Income Growth Pattern
Below is the plot of the Net Income of IO Biotech over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in IO Biotech financial statement analysis. It represents the amount of money remaining after all of IO Biotech operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is IO Biotech's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in IO Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (95.49 M) | 10 Years Trend |
|
Net Income |
| Timeline |
IOBT Net Income Regression Statistics
| Arithmetic Mean | (36,271,994) | |
| Coefficient Of Variation | (99.18) | |
| Mean Deviation | 32,877,639 | |
| Median | (10,749,000) | |
| Standard Deviation | 35,973,902 | |
| Sample Variance | 1294.1T | |
| Range | 84.7M | |
| R-Value | (0.85) | |
| Mean Square Error | 388.2T | |
| R-Squared | 0.72 | |
| Significance | 0.000017 | |
| Slope | (6,039,716) | |
| Total Sum of Squares | 20705.9T |
IOBT Net Income History
Other Fundumenentals of IO Biotech
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
IO Biotech Net Income component correlations
IOBT Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for IO Biotech is extremely important. It helps to project a fair market value of IOBT Stock properly, considering its historical fundamentals such as Net Income. Since IO Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of IO Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of IO Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will IOBT introduce new products? Factors like these will boost the valuation of IO Biotech. Market participants price IOBT higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about IO Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
IO Biotech's market price often diverges from its book value, the accounting figure shown on IOBT's balance sheet. Smart investors calculate IO Biotech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since IO Biotech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between IO Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if IO Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IO Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
IO Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to IO Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of IO Biotech.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in IO Biotech on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding IO Biotech or generate 0.0% return on investment in IO Biotech over 90 days. IO Biotech is related to or competes with Werewolf Therapeutics, Spruce Biosciences, Adicet Bio, OUTLOOK THERAPEUTICS, Cue Biopharma, Karyopharm Therapeutics, and NRX Pharmaceuticals. IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T... More
IO Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure IO Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess IO Biotech upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 151.49 | |||
| Value At Risk | (16.22) | |||
| Potential Upside | 13.33 |
IO Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for IO Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as IO Biotech's standard deviation. In reality, there are many statistical measures that can use IO Biotech historical prices to predict the future IO Biotech's volatility.| Risk Adjusted Performance | 7.0E-4 | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (1.47) | |||
| Treynor Ratio | (0.50) |
IO Biotech February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 7.0E-4 | |||
| Market Risk Adjusted Performance | (0.49) | |||
| Mean Deviation | 9.12 | |||
| Coefficient Of Variation | (8,188) | |||
| Standard Deviation | 19.52 | |||
| Variance | 381.17 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.27) | |||
| Total Risk Alpha | (1.47) | |||
| Treynor Ratio | (0.50) | |||
| Maximum Drawdown | 151.49 | |||
| Value At Risk | (16.22) | |||
| Potential Upside | 13.33 | |||
| Skewness | 4.1 | |||
| Kurtosis | 30.43 |
IO Biotech Backtested Returns
IO Biotech retains Efficiency (Sharpe Ratio) of -0.0148, which attests that the entity had a -0.0148 % return per unit of price deviation over the last 3 months. IO Biotech exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out IO Biotech's Information Ratio of (0.02), market risk adjusted performance of (0.49), and Coefficient Of Variation of (8,188) to validate the risk estimate we provide. The company owns a Beta (Systematic Risk) of 0.5, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, IO Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding IO Biotech is expected to be smaller as well. At this point, IO Biotech has a negative expected return of -0.3%. Please make sure to check out IO Biotech's total risk alpha, as well as the relationship between the skewness and day median price , to decide if IO Biotech performance from the past will be repeated sooner or later.
Auto-correlation | 0.42 |
Average predictability
IO Biotech has average predictability. Overlapping area represents the amount of predictability between IO Biotech time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of IO Biotech price movement. The serial correlation of 0.42 indicates that just about 42.0% of current IO Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.42 | |
| Spearman Rank Test | 0.45 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
IOBT Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, IO Biotech reported net income of (95.49 Million). This is 127.98% lower than that of the Biotechnology sector and 236.33% lower than that of the Health Care industry. The net income for all United States stocks is 116.72% higher than that of the company.
IOBT Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IO Biotech's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IO Biotech could also be used in its relative valuation, which is a method of valuing IO Biotech by comparing valuation metrics of similar companies.IO Biotech is currently under evaluation in net income category among its peers.
IO Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in IO Biotech that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of IO Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing IO Biotech's value.| Shares | Sectoral Asset Management Inc | 2025-06-30 | 117.7 K | Bridgeway Capital Management, Llc | 2025-06-30 | 75 K | Geode Capital Management, Llc | 2025-06-30 | 33.3 K | Xtx Topco Ltd | 2025-06-30 | 29.2 K | Citadel Advisors Llc | 2025-06-30 | 28.9 K | Jane Street Group Llc | 2025-06-30 | 25.9 K | Goss Wealth Management Llc | 2025-06-30 | 24.2 K | Ubs Group Ag | 2025-06-30 | 13.3 K | Cubist Systematic Strategies, Llc | 2025-06-30 | 13.1 K | Vivo Capital, Llc | 2025-06-30 | 6.2 M | Novo A/s | 2025-06-30 | 3.4 M |
IOBT Fundamentals
| Return On Equity | -2.4 | ||||
| Return On Asset | -0.89 | ||||
| Current Valuation | 10.21 M | ||||
| Shares Outstanding | 71.95 M | ||||
| Shares Owned By Insiders | 5.14 % | ||||
| Shares Owned By Institutions | 44.66 % | ||||
| Number Of Shares Shorted | 3.08 M | ||||
| Price To Book | 22.91 X | ||||
| Gross Profit | (2.59 M) | ||||
| EBITDA | (93.2 M) | ||||
| Net Income | (95.49 M) | ||||
| Cash And Equivalents | 170.12 M | ||||
| Cash Per Share | 5.90 X | ||||
| Total Debt | 1.92 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 20.94 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (82.35 M) | ||||
| Short Ratio | 4.30 X | ||||
| Earnings Per Share | (1.34) X | ||||
| Target Price | 2.18 | ||||
| Number Of Employees | 80 | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 20.87 M | ||||
| Total Asset | 67.7 M | ||||
| Retained Earnings | (359.31 M) | ||||
| Working Capital | 45.47 M | ||||
| Net Asset | 67.7 M |
About IO Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IO Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IO Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IO Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.